Study of Paxlovid safety and effectiveness in high-risk COVID-19
Part of Infections, Lungs & breathing clinical trials.
This study observes people at higher risk for severe COVID-19 who take Paxlovid, to better understand how well it works and how safe it is in real-world use. It may help doctors confirm the best way to use Paxlovid and spot any side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are taking Paxlovid now, already took it, or plan to start it soon as allowed locally
- You can (or your legal representative can) sign written consent before joining the study
- You do not have a known reason you cannot take Paxlovid based on the approved label
- You will not take any other investigational (study) medicine during the observation period
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks how Paxlovid works in everyday care for people who are hospitalized with confirmed COVID-19. If you have a positive COVID-19 test and mild to moderate symptoms, this trial may help doctors understand how well the treatment performs outside of tightly controlled settings.
This study tests the best combination and timing of antiviral medicines for people with COVID-19 who have weakened immune systems. It aims to improve outcomes in people with mild to moderate illness.
This trial tests whether an optimized antiviral treatment can help people with weakened immune systems who have COVID-19. It aims to find the best way to treat them to prevent severe illness.
This trial tests a longer course of remdesivir plus Paxlovid (nirmatrelvir/ritonavir) for immunocompromised people with persistent COVID-19. It aims to see if combining these two antiviral medicines can help clear the virus more effectively.
This trial looks at how well an antiviral works in the body when started early in people with COVID-19 symptoms. You may be able to join if you’re an otherwise healthy adult with confirmed infection and symptoms for less than 4 days.
This trial tests an investigational drug called MDX2301 to see if it's safe in healthy adults and in adults who are at higher risk for severe COVID-19. Higher risk means you have conditions like asthma, diabetes, heart disease, or other listed health issues.
Hear when a new COVID-19 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.